📚 Lecture Overview
This lecture covers the fundamental lines of diabetes management, emphasizing lifestyle modifications, glycemic targets, and detailed pharmacological profiles of oral and injectable anti-diabetic medications. Mastering these agents, their mechanisms, advantages, and side effects is crucial for tailoring individualized patient care and passing clinical exams.
🎯 Key Concepts & Definitions
- Medical Nutrition Therapy (MNT): Individualized meal planning focusing on nutrient quality, whole foods, and a minimum 5% weight loss for overweight or obese patients.
- Glycemic Targets: Standard treatment goals including A1C <7.0%, pre-prandial glucose of 80–130 mg/dL, and peak postprandial glucose <180 mg/dL.
- Insulin Secretagogues: Medications (like Sulphonylureas) that stimulate insulin secretion in a glucose-independent manner, carrying a higher risk of hypoglycemia.
- Insulin Sensitizers: Medications (like Pioglitazone and Metformin) that improve the body's sensitivity to existing insulin.
- Glucosuria: Excretion of glucose in the urine, a primary mechanism of SGLT2 inhibitors.
📖 Main Content
1. General Management & Lifestyle
- Medical Nutrition Therapy (MNT):
- Aim for a minimum weight loss of 5% via behavioral modification for overweight/obese patients.
- Include non-starchy vegetables, whole fruits, legumes, whole grains, nuts/seeds, and low-fat dairy.
- Minimize sugar-sweetened beverages, sweets, refined grains, and ultra-processed foods.
- Physical Activity:
- 150 minutes or more of moderate-to-vigorous aerobic activity per week (spread over at least 3 days, max 2 consecutive days without exercise).
- 2–3 sessions/week of resistance exercise on non-consecutive days.
- Interrupt prolonged sitting every 30 minutes.
2. Glycemic Targets
- A1C: < 7.0%
- Pre-prandial capillary plasma glucose: 80–130 mg/dL
- Peak postprandial capillary plasma glucose: < 180 mg/dL
3. Oral Anti-Diabetic Medications & Injectables
- Metformin:
- Action: Inhibits hepatic glucose production.
- Efficacy: High | Hypoglycemia: Rare | Weight: Neutral to modest loss (1-2 kg).
- Effects: Potential CVD benefit; neutral for HF and DKD.
- Side effects: GI upset (diarrhea), Vitamin B12 deficiency, lactic acidosis (extremely rare).
- Contraindication: eGFR < 30 ml/min and advanced liver disease.
- SGLT2 Inhibitors:
- Action: Blocks glucose reabsorption by the kidney, increasing glucosuria.
- Efficacy: Intermediate–high | Hypoglycemia: Rare | Weight: Decrease (~3-4 kg).
- Effects: Benefit for CVD, Heart Failure (HF), and Diabetic Kidney Disease (DKD).
- Side effects: Genitourinary infections, UTIs, polyuria, volume depletion/dizziness, euglycemic DKA (rare).
- DPP-4 Inhibitors:
- Action: Increases insulin and decreases glucagon secretion (glucose-dependent).
- Efficacy: Intermediate | Hypoglycemia: Rare | Weight: Neutral.
- Effects: Neutral for CVD, HF (except Saxagliptin), and DKD.
- Side effects: Well tolerated; rare arthralgia or pancreatitis.
- Pioglitazone (Thiazolidinediones):
- Action: Increases insulin sensitivity (only available insulin-sensitizer).
- Efficacy: High | Hypoglycemia: Rare | Weight: Increase significantly.
- Effects: Potential CVD benefit; increased risk of Heart Failure (HF); neutral for DKD.
- Side effects: Edema, bone loss/fractures, bladder cancer risk, macular edema, benefit in NASH.
- Sulphonylureas:
- Action: Insulin secretagogue (glucose-independent).
- Efficacy: High | Hypoglycemia: Increased | Weight: Increase.
- Effects: Neutral for CVD, HF, and DKD. Inexpensive.
- Alpha-Glucosidase Inhibitors (Acarbose, Miglitol):
- Reduces postprandial glucose excursions with no hypoglycemia (if used alone) and no weight gain.
- Disadvantages include frequent GI side effects and frequent dosing schedules.
- Glitinides (e.g., Repaglinide):
- Shorter-acting secretagogues with less risk of hypoglycemia and weight gain compared to Sulphonylureas.
- GLP-1 Receptor Agonists (Injectable):
- High efficacy, major weight loss, and beneficial cardiovascular effects with no hypoglycemia.
- Examples: Liraglutide (daily subcutaneous) and Semaglutide (oral daily or weekly subcutaneous).
📊 Visual Learning
flowchart TD
A[Diabetes Management] --> B[Lifestyle]
A --> C[Pharmacotherapy]
B --> D[MNT 5 pct Weight Loss]
B --> E[Exercise 150 min week]
C --> F[Oral Agents]
C --> G[Injectables]
mindmap
root("Oral Anti-Diabetics")
"Metformin"
"Hepatic glucose inhibition"
"No hypoglycemia"
"eGFR limit < 30"
"SGLT2 Inhibitors"
"Renal glucose blocking"
"Weight loss"
"Heart failure benefit"
"Sulphonylureas"
"Insulin secretagogue"
"Hypoglycemia risk"
"Weight gain"
"Pioglitazone"
"Insulin sensitizer"
"Heart failure risk"
"Weight increase"
graph LR
A[A1C Target < 7 pct] --> B[Pre-prandial 80 to 130]
A --> C[Postprandial < 180]
💡 Important Points to Remember
- Metformin First Line: High efficacy, rare hypoglycemia, neutral weight, and cheap, but contraindicated if eGFR < 30 ml/min.
- Heart Failure & Kidney Protectors: SGLT2 inhibitors provide proven renal and heart failure benefits.
- Heart Failure Dangers: Pioglitazone is contraindicated or high risk in Heart Failure due to fluid retention and edema.
- Hypoglycemia Culprits: Sulphonylureas carry a high risk of hypoglycemia because they are glucose-independent secretagogues.
- Weight Neutral vs. Gain vs. Loss:
- Weight Loss/Decrease: SGLT2 inhibitors, GLP-1 RAs, Metformin (modest).
- Weight Neutral: DPP-4 inhibitors.
- Weight Gain: Sulphonylureas, Pioglitazone.
- Glucose-Dependent Action: DPP-4 inhibitors work in a glucose-dependent manner, lowering hypoglycemia risk.
- MNT Goal: Aim for at least 5% weight loss in overweight/obese patients.
- Exercise Rule: 150+ minutes of aerobic activity weekly, broken up with no more than 2 consecutive rest days, plus 2-3 resistance sessions.
⚠️ Common Exam Questions
- Exam Traps in MCQs:
- Examiners love to test contraindications—e.g., prescribing Metformin to a patient with an eGFR of 25 ml/min, or prescribing Pioglitazone to a patient with severe Heart Failure.
- Confusing glucose-dependent medications (DPP-4 inhibitors, low hypoglycemia risk) with glucose-independent secretagogues (Sulphonylureas, high hypoglycemia risk).
- Forgetting that SGLT2 inhibitors cause volume depletion, UTIs, and euglycemic DKA despite their profound cardiovascular and renal benefits.
📝 Quick Review Checklist
I can explain the lifestyle modifications (MNT and physical activity targets)
I understand the core glycemic targets (A1C, pre- and post-prandial glucose)
I can define the mechanism and side effects of Metformin
I know which drugs cause weight gain vs. weight loss
I understand the organ-protective benefits of SGLT2 inhibitors
I know the major contraindications for Pioglitazone and Metformin